Celgene Corporation / Abraxis BioScience Inc.

Metastatic Pancreatic Cancer

68K US cases/yr

Disease Overview

Pancreatic adenocarcinoma is among the most lethal solid tumors, with most patients diagnosed at advanced stage and limited response to conventional cytotoxics. It accounts for roughly 3% of US cancers but 8% of cancer deaths. Treatment options at the time of the Celgene-Abraxis deal were largely confined to gemcitabine monotherapy.

Competitive Landscape

At the time of Celgene's 2010 acquisition of Abraxis, Abraxane (nab-paclitaxel) was approved only in metastatic breast cancer (FDA 2005), with NSCLC (2012) and pancreatic (2013) approvals still pending. The competitive set in pancreatic cancer was thin: Eli Lilly's Gemzar (gemcitabine) was the standard of care, with FOLFIRINOX emerging in academic centers as a more aggressive but toxic alternative. In breast cancer, Abraxane competed with conventional Taxol (paclitaxel, BMS) and Taxotere (docetaxel, Sanofi), differentiating on its solvent-free albumin-bound formulation that allowed higher dosing without Cremophor-related hypersensitivity. The deal gave Celgene its first solid-tumor asset to complement its hematology franchise (Revlimid, Vidaza) and was structured with a CVR tied to lung and pancreatic approval and royalty milestones, signaling Celgene's view that Abraxane's value depended on label expansion. The 2013 MPACT trial (Abraxane + gemcitabine vs gemcitabine alone) ultimately validated the thesis, making nab-paclitaxel + gemcitabine a first-line standard before Onivyde and FOLFIRINOX-based regimens came to dominate. (Sources: https://en.wikipedia.org/wiki/Abraxane; https://www.fiercebiotech.com/financials/celgene-strikes-2-9b-deal-to-acquire-abraxis)